61.90
-0.75 (-1.20%)
| Previous Close | 62.65 |
| Open | 62.60 |
| Volume | 5,499,886 |
| Avg. Volume (3M) | 2,225,704 |
| Market Cap | 7,279,254,528 |
| Price / Earnings (TTM) | 13.06 |
| Price / Earnings (Forward) | 8.19 |
| Price / Sales | 6.40 |
| Price / Book | 14.78 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | 44.76% |
| Operating Margin (TTM) | 53.44% |
| Diluted EPS (TTM) | 3.76 |
| Quarterly Revenue Growth (YOY) | 35.20% |
| Quarterly Earnings Growth (YOY) | 53.70% |
| Total Debt/Equity (MRQ) | 318.67% |
| Current Ratio (MRQ) | 8.39 |
| Operating Cash Flow (TTM) | 503.86 M |
| Levered Free Cash Flow (TTM) | 402.43 M |
| Return on Assets (TTM) | 18.50% |
| Return on Equity (TTM) | 147.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Halozyme Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.60 |
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.11% |
| % Held by Institutions | 101.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Snyder Capital Management L P | 30 Sep 2025 | 2,733,844 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 92.00 (Citizens, 48.63%) | Buy |
| Median | 79.00 (27.63%) | |
| Low | 56.00 (Goldman Sachs, -9.53%) | Hold |
| Average | 77.43 (25.09%) | |
| Total | 4 Buy, 3 Hold | |
| Avg. Price @ Call | 69.17 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 28 Nov 2025 | 90.00 (45.40%) | Buy | 71.40 |
| 15 Oct 2025 | 90.00 (45.40%) | Buy | 66.36 | |
| Goldman Sachs | 18 Nov 2025 | 56.00 (-9.53%) | Hold | 70.10 |
| Citizens | 04 Nov 2025 | 92.00 (48.63%) | Buy | 68.05 |
| JP Morgan | 27 Oct 2025 | 65.00 (5.01%) | Hold | 65.85 |
| Morgan Stanley | 20 Oct 2025 | 79.00 (27.63%) | Buy | 66.47 |
| Leerink Partners | 14 Oct 2025 | 70.00 (13.09%) | Hold | 66.65 |
| Benchmark | 24 Sep 2025 | 90.00 (45.40%) | Buy | 75.64 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CONNAUGHTON BERNADETTE | - | 68.10 | -829 | -56,455 |
| TORLEY HELEN | - | 68.10 | -16,569 | -1,128,349 |
| Aggregate Net Quantity | -17,398 | |||
| Aggregate Net Value ($) | -1,184,804 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 68.10 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TORLEY HELEN | Officer | 01 Dec 2025 | Automatic sell (-) | 16,569 | 68.10 | 1,128,349 |
| TORLEY HELEN | Officer | 01 Dec 2025 | Option execute | 16,569 | - | - |
| CONNAUGHTON BERNADETTE | Director | 01 Dec 2025 | Automatic sell (-) | 829 | 68.10 | 56,455 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |